Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887702 · ClinicalTrials.gov registry record · Phase 3
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT03887702 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 4 participants.
The verdict
NCT03887702, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase III trial studies the effect of hepatitis B antiviral (anti-HBV) therapy in preventing liver complications in patients with chronic or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing therapy for cancer are at an increased risk for changes in the liver which could be minor or severe. Anti-HBV therapy acts against infections caused by HBV and may help reduce the chance that HBV gets worse or comes back in patients receiving anti-cancer therapy for solid tumors.
Interventions
- OTHER Best Practice
- DRUG Tenofovir Alafenamide
- DRUG Tenofovir Disoproxil Fumarate
- DRUG Entecavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-01-17 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03887702
The ClinicalTrials.gov registry entry for NCT03887702 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Best Practice is the first listed.
NCT03887702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03887702 about?
NCT03887702 is a clinical study titled "Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors". This phase III trial studies the effect of hepatitis B antiviral (anti-HBV) therapy in preventing liver complications in patients with chronic or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing therapy for cancer...
What is the current status of trial NCT03887702?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2020-01-17. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT03887702?
The interventions under investigation include: Best Practice (OTHER), Tenofovir Alafenamide (DRUG), Tenofovir Disoproxil Fumarate (DRUG), Entecavir (DRUG).
Who is sponsoring clinical trial NCT03887702?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.